Kyle R. Crassini, MBBS, PhD
Affiliations: | 2019 | Faculty of Medicine and Health | University of Sydney, Camperdown, New South Wales, Australia |
Area:
Haematology, Molecular geneticsGoogle:
"Kyle Crassini"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| O. Giles Best | grad student | 2019 | University of Sydney | |
| (PhD "Novel therapies, mRNA expression profiling and immune failure in chronic lymphocytic leukaemia (CLL); applications for in vitro research and clinical management", Source: Personal communicatipn) | ||||
| Stephen P. Mulligan | grad student | 2019 | University of Sydney | |
| (PhD "Novel therapies, mRNA expression profiling and immune failure in chronic lymphocytic leukaemia (CLL); applications for in vitro research and clinical management", Source: Personal communicatipn) | ||||
| William Stevenson | grad student | 2019 | University of Sydney | |
| (PhD "Novel therapies, mRNA expression profiling and immune failure in chronic lymphocytic leukaemia (CLL); applications for in vitro research and clinical management", Source: Personal communicatipn) | ||||
| Christopher Ward | grad student | 2019 | University of Sydney | |
| (PhD "Novel therapies, mRNA expression profiling and immune failure in chronic lymphocytic leukaemia (CLL); applications for in vitro research and clinical management", Source: Personal communication) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fatima N, Shen Y, Crassini K, et al. (2024) The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells . Leukemia & Lymphoma. 1-13 |
| Crassini K, Gibson J. (2023) Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies. Internal Medicine Journal |
| Anderson MA, Bennett R, Badoux X, et al. (2023) Chronic lymphocytic leukaemia Australasian consensus practice statement. Internal Medicine Journal. 53: 1678-1691 |
| Fatima N, Shen Y, Crassini K, et al. (2021) The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. Ejhaem. 2: 81-93 |
| Fatima N, Crassini KR, Thurgood L, et al. (2020) Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia. Cancer Drug Resistance (Alhambra, Calif.). 3: 532-549 |
| Shen Y, Crassini K, Fatima N, et al. (2020) IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. Blood Advances. 4: 5093-5106 |
| Crassini K, Stevenson WS, Mulligan SP, et al. (2019) Molecular pathogenesis of chronic lymphocytic leukaemia. British Journal of Haematology |
| Shen Y, Crassini K, Sandhu S, et al. (2019) Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. Leukemia & Lymphoma. 1-12 |
| Fatima N, Shen Y, Crassini KR, et al. (2019) TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status Blood. 134: 1735-1735 |
| Shen Y, Crassini KR, Fatima N, et al. (2019) Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment Blood. 134: 5443-5443 |